Comparison tool

PT-141 vs Melanotan II side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

PT-141Melanotan II

Share this peptide comparison

Property	PT-141	Melanotan II
Category	Sexual Health	Sexual Health
Also known as	Bremelanotide, Vyleesi	MT-II, MT2, Melanotan 2
FDA approved	Yes	No
Clinical status	FDA Approved for HSDD in premenopausal women Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Sexual desire, erectile dysfunction, low libido	Tanning, libido enhancement, erectile function
How it works	PT-141, also known as bremelanotide, is described as a melanocortin peptide with central nervous system activity. The supplied source points to melanocortin receptor activation in hypothalamic pathways, mainly MC4R with some MC3R involvement, as the proposed route for effects on sexual desire and arousal. The source contrasts this with PDE5 inhibitors by noting that PT-141 is not primarily framed as a genital blood-flow drug. Reported nausea and temporary blood-pressure or heart-rate changes are also linked by the source to melanocortin receptor activity.	Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.
Typical dosing	1.75 mg as needed · As needed, at least 45 min before activity	250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection
Research dosing	1.75 mg · As needed, at least 45 min before activity · Subcutaneous injection; autoinjector available	250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection
Typical duration	As needed, at least 45 min before activity	Loading phase 2-3 weeks, then maintenance
Administration	Subcutaneous injection; autoinjector form reported	Subcutaneous injection
Timing	1-2 hours before sexual activity With or without food	Evening or before sun exposure With or without food
Evidence level	FDA Approved	Research
Possible side effects	Nausea (Source reports nausea around 40% and identifies it as the most common adverse effect.) Facial flushing (Source reports facial flushing around 20%.) Injection-site reactions (Reported in the source without a quantified severity note.) +5 more Headache (Reported in the source without a quantified severity note.) Transient blood pressure increase (Source notes temporary blood-pressure elevation as a safety consideration.) Skin hyperpigmentation with frequent use (Reported in the source in connection with frequent use.) Vomiting (Reported in the source without a quantified severity note.) Fatigue (Reported in the source without a quantified severity note.)	Nausea (Reported as common, especially initially.) Facial flushing Fatigue +6 more Spontaneous penile erections Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.) Priapism (Source flags this as an emergency-risk adverse event.) Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)
Research summary	The source presents PT-141/bremelanotide as a peptide with comparatively strong clinical evidence because it completed an FDA program for a defined indication. It summarizes two phase 3 RECONNECT studies involving 1,267 premenopausal women with HSDD who received as-needed 1.75 mg subcutaneous bremelanotide or placebo. Reported outcomes included statistically significant improvements in sexual desire and distress related to low desire, while the source characterizes the absolute benefit as modest. It also notes nausea in about 40% of women, discontinuations related to nausea, and a cap of 8 doses per month. Evidence for male libido or erectile dysfunction use is described as off-label and less developed than the approved HSDD indication.	The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.
References	PubMed PubMed +2 more ClinicalTrials.gov PubMed	WikipediaMelanotan II PubMedPubMed record 11018622 +1 more DermNetMelanotan II
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

PT-141

Melanotan II

Category

Sexual Health

Also known as

Bremelanotide, Vyleesi

MT-II, MT2, Melanotan 2

FDA approved

Yes

Clinical status

FDA Approved for HSDD in premenopausal women

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Not approved; research reportedly discontinued due to side effects. Source also lists FDA Category 2 restricted status tied to melanoma risk and other safety concerns.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Sexual desire, erectile dysfunction, low libido

Tanning, libido enhancement, erectile function

How it works

PT-141, also known as bremelanotide, is described as a melanocortin peptide with central nervous system activity. The supplied source points to melanocortin receptor activation in hypothalamic pathways, mainly MC4R with some MC3R involvement, as the proposed route for effects on sexual desire and arousal. The source contrasts this with PDE5 inhibitors by noting that PT-141 is not primarily framed as a genital blood-flow drug. Reported nausea and temporary blood-pressure or heart-rate changes are also linked by the source to melanocortin receptor activity.

Melanotan II is reported as a broad melanocortin receptor agonist rather than a receptor-selective compound. The source names MC1, MC3, MC4, and MC5 as targets. MC1 signaling in melanocytes is tied to melanin production, while MC4 signaling in the central nervous system is linked to sexual arousal and desire pathways. The broad receptor profile is also presented as a reason for a wider adverse-effect profile.

Typical dosing

1.75 mg as needed · As needed, at least 45 min before activity

250-500 mcg daily (loading), then 500-1,000 mcg weekly (maintenance) · Daily during loading (1-2 weeks), then weekly maintenance · Loading 1-2 weeks, then maintenance · Subcutaneous injection

Research dosing

1.75 mg · As needed, at least 45 min before activity · Subcutaneous injection; autoinjector available

250-500 mcg initially · Loading phase 2-3 weeks, then maintenance · Subcutaneous injection

Typical duration

As needed, at least 45 min before activity

Loading phase 2-3 weeks, then maintenance

Administration

Subcutaneous injection; autoinjector form reported

Subcutaneous injection

Timing

1-2 hours before sexual activity

With or without food

Evening or before sun exposure

With or without food

Evidence level

FDA Approved

Research

Possible side effects

Nausea (Source reports nausea around 40% and identifies it as the most common adverse effect.)
Facial flushing (Source reports facial flushing around 20%.)
Injection-site reactions (Reported in the source without a quantified severity note.)

+5 more

Headache (Reported in the source without a quantified severity note.)
Transient blood pressure increase (Source notes temporary blood-pressure elevation as a safety consideration.)
Skin hyperpigmentation with frequent use (Reported in the source in connection with frequent use.)
Vomiting (Reported in the source without a quantified severity note.)
Fatigue (Reported in the source without a quantified severity note.)

Nausea (Reported as common, especially initially.)
Facial flushing
Fatigue

+6 more

Spontaneous penile erections
Darkening of skin and moles (Source highlights mole changes and pigmentation concerns.)
Priapism (Source flags this as an emergency-risk adverse event.)
Association with melanoma risk (Source links restricted status and dermatology cautions to melanoma risk concerns.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Legal restriction caution (Source reports illegality in the US, UK, and Australia; this regulatory claim needs admin review.)

Research summary

The source presents PT-141/bremelanotide as a peptide with comparatively strong clinical evidence because it completed an FDA program for a defined indication. It summarizes two phase 3 RECONNECT studies involving 1,267 premenopausal women with HSDD who received as-needed 1.75 mg subcutaneous bremelanotide or placebo. Reported outcomes included statistically significant improvements in sexual desire and distress related to low desire, while the source characterizes the absolute benefit as modest. It also notes nausea in about 40% of women, discontinuations related to nausea, and a cap of 8 doses per month. Evidence for male libido or erectile dysfunction use is described as off-label and less developed than the approved HSDD indication.

The supplied research summary describes narrow older human evidence for erectile-function outcomes. In men with organic erectile dysfunction, the source reports subjectively described erections after 12 of 19 Melanotan II injections compared with 1 of 21 placebo doses, plus longer rigidity periods and greater sexual interest; nausea and yawning were frequent. The source connects this effect profile to later bremelanotide development. For tanning, the same source emphasizes lack of large safety trials and dermatology concerns including changing moles, melanoma reports, uneven or lasting pigmentation changes, nausea, and risks from unregulated injected material.

References

PubMed PubMed

+2 more

ClinicalTrials.gov PubMed

WikipediaMelanotan II PubMedPubMed record 11018622

+1 more

DermNetMelanotan II

Full profile

View Details